BC Extra | Aug 10, 2019
Company News

Aug. 9 Company Quick Takes: Nektar, Novo, Biktarvy, Autolus and more

Nektar tumbles on bempegaldesleukin revelation   Nektar Therapeutics (NASDAQ:NKTR) fell $8.65 (29%) to close at $20.92 after reporting during its 2Q19 earnings call late Thursday that it had connected decreasing responses seen in a trial...
BC Innovations | Nov 6, 2017
Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Cell culture and mouse studies suggest GHRH receptor agonists could help treat heart failure. In a rat cardiomyoblast cell line, primary rat ventricular myocytes and human induced pluripotent stem (iPS) cell-derived cardiomyocyte...
BC Week In Review | Oct 5, 2015
Company News

Theratechnologies, BL&H deal

Theratechnologies granted BL&H rights to develop and commercialize Egrifta tesamorelin in South Korea to treat HIV-associated lipodystrophy. BL&H is responsible for registration in the territory and will distribute the analog of growth hormone-releasing factor through...
BC Week In Review | Sep 14, 2015
Company News

Theratechnologies, AOP Orphan sales and marketing update

Egrifta tesamorelin to treat lipodystrophy in HIV patients is now available in European countries as part of a named-patient program. The analog of growth hormone-releasing factor is available in the U.S. and Canada. Earlier this...
BC Week In Review | Mar 16, 2015
Company News

Theratechnologies, AOP Orphan deal

Theratechnologies granted AOP Orphan exclusive rights to develop and commercialize Egrifta tesamorelin in select countries within Europe. AOP Orphan will distribute Egrifta in the countries through Named Patient Sales Programs and will be responsible for...
BC Week In Review | Sep 15, 2014
Company News

Theratechnologies, Merck KGaA sales and marketing update

Theratechnologies said it sent a first shipment of 1 mg Egrifta tesamorelin to its U.S. distributor and that the analog of growth hormone-releasing factor will be available in the U.S. by mid-September. The product is...
BC Week In Review | May 5, 2014
Company News

Actelion, Theratechnologies, Merck KGaA deal

The companies completed the return of U.S. rights to Egrifta tesamorelin to Theratechnologies from Merck's EMD Serono Inc. subsidiary. The analog of growth hormone-releasing factor is approved to treat excess abdominal fat in HIV patients...
BC Week In Review | Feb 24, 2014
Company News

Theratechnologies sales and marketing update

Theratechnologies said on Feb. 14 that it expects inventory of Egrifta tesamorelin to be depleted "in the coming weeks" due to manufacturing delays and production issues and that it would temporarily cease manufacture of Egrifta....
BioCentury | Feb 24, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/21 cls NPS Pharmaceuticals Inc. (NASDAQ:NPSP) Jefferies Eun Yang Downgrade Hold (from buy) 4% $38.57 Yang downgraded on valuation and maintained her $38 target....
BC Week In Review | Dec 23, 2013
Company News

Theratechnologies, Merck KGaA deal

Theratechnologies will regain U.S. rights to Egrifta tesamorelin from Merck's EMD Serono Inc. subsidiary for $20 million after the partners agreed to terminate their 2008 deal. Theratechnologies will pay the $20 million in equal payments...
Items per page:
1 - 10 of 176